SGLT2 Inhibitors Tied to Lower Risk in Patients with Diabetes and Cirrhosis Recently updated !
A rigorous cohort study utilizing Taiwan’s National Health Insurance Database provides robust evidence that SGLT2 inhibitors offer superior multi-organ protection for the complex population of patients with both type 2 diabetes and liver cirrhosis. Among 24,259 adults (average age 64.7 years; 33.9% female) followed for a median of 2.3 years, […]
